The efficacy of switching from sulfonyl urea to repaglinide on glycemic control in elderly patients with type 2 diabetes
Phase 4
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000022531
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
HbA1c was not significantly different between the two groups (SU +0.02% vs Repa -0.07%), while greater improvements in the glycated albumin (GA) and GA to HbA1c ratio (GA/HbA1c) were observed in the Repa group without increasing hypoglycemia. When the Repa group was subdivided according to whether GA improved, the SU dose before switching to repaglinide was significantly smaller and the HOMA-beta was significantly higher in the GA improvement subgroup.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 57
Inclusion Criteria
Not provided
Exclusion Criteria
1)patients with hypersensitivity to repaglinide 2) patients with severe liver dysfunction 3)patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method